½ÃÀ庸°í¼­
»óǰÄÚµå
1363446

Áú ½½¸µ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023³â-2030³â)

Vaginal Slings Market Size, Share & Trends Analysis Report By Product (Tension-Free Vaginal Tape Slings, Transobturator Slings, and Mini-Slings), By Type (Midurethral sling, Traditional sling), By End Use, By Region, And Segment Forecast, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áú ½½¸µ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è Áú ½½¸µ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 26¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, 2023³âºÎÅÍ 2030³â±îÁöÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 4.62%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¿©¼ºÀÇ ¶óÀÌÇÁ ½ºÅ¸ÀÏ º¯È­, Áú ½½¸µ Ä¡·á ¹× ¼ö¼ú¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁý´Ï´Ù. °Ô´Ù°¡ ³·Àº ħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¿©¼º ³ë³â Àα¸ Áõ°¡, ½ºÆ®·¹½º ¿ä½Ç±Ý À¯º´·ü Áõ°¡ µîÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ö¿ä¸¦ ³ôÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿©¼ºÀÇ ½ºÆ®·¹½º ¼º ¿ä½Ç±ÝÀ» ÀÏÀ¸Å°´Â À§Çè ÀÎÀÚ´Â Àڱà Ż, ´ç´¢º´, ¸¸¼º ±âħ, Àڱà ÀûÃâ µîÀÇ °ñ¹Ý ¼ö¼ú, ºñ¸¸, °»³â±â Àå¾Ö, Ç㸮¿Í °ñ¹ÝÀÇ ½Å°æ ¼Õ»ó, ÀӽŠ¹× Ãâ»ê(ƯÈ÷ °æÁú ºÐ¸¸) µîÀÌ ÀÖ½À´Ï´Ù. °Ô´Ù°¡ John Wiley &Sons, Inc.ÀÇ Á¶»ç ³í¹®¿¡ µû¸£¸é ½ÅÈï±¹ ¿©¼ºÀÇ ¾à 26%°¡ ¿ä½Ç±ÝÀ¸·Î °íÅë¹Þ°í ÀÖÀ¸¸ç, ±× ¹ß»ý·üÀº ½ºÆ®·¹½º¼º ¿ä½Ç±Ý(12.6%)ÀÌ È¥ÇÕ¼º ¿ä½Ç±Ý(9.1%)¿Í Àý¹Ú¼º ¿ä½Ç±Ý(5.3%)º¸´Ù ³ô½À´Ï´Ù. ½ºÆ®·¹½º ¼º ¿ä½Ç±ÝÀº ¿©¼ºÀÇ QOL¿¡ ½É°¢ÇÑ ¿µÇâÀ» ¹ÌÄ¡¸ç Á¤½Å Àå¾Ö, ³ëµ¿ »ý»ê¼º °¨¼Ò, »ç¸Á·ü »ó½Â ¹× »çȸÀû °í¸³À» ÃÊ·¡ÇÕ´Ï´Ù. µû¶ó¼­ ¿ä½Ç±Ý ¹ß»ý·üÀÌ Áõ°¡Çϸé Áú ½½¸µ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ°í ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¿ä½Ç±ÝÀº ³ëÀÎ Àα¸¿¡ ¸Å¿ì ¸¹Àº Áúº´ÀÔ´Ï´Ù. 2021³â ±¹°¡ Åë°è±¹ÀÇ º¸°í¿¡ µû¸£¸é 2021³â 60¼¼ ÀÌ»óÀÇ ¿©¼ºÀº 7100¸¸ ¸íÀ¸·Î, 2031³â¿¡´Â ±× ¼ö°¡ 1¾ï 100¸¸ ¸í¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ ¿©¼º ³ëÀÎ Àα¸ Áõ°¡´Â Á¶»ç ±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, Áú ½½¸µ ¼ö¼úÀº ¾ÈÀüÇϰí È¿À²ÀûÀ̸ç È¿°úÀûÀ̸ç ÃÖ¼ÒÇÑÀÇ Ä¡·á¿Í ¾à 30-45 ºÐÀÇ È¸º¹ ½Ã°£ÀÌ ÇÊ¿äÇÏ´Ù´Â °ÍÀ» ¾Ë°í ÀÖ½À´Ï´Ù. Àú ħ½À ¼ö¼úÀº Áú ¸Þ½¬¿Í ÄÝÆ÷ ¼­½ºÆæ¼Ç°ú °°Àº ÀüÅëÀûÀÎ ¹æ¹ýÀ» ´ëüÇÕ´Ï´Ù. µû¶ó¼­ ³·Àº ħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Medicare & Medicad Services(CMS) Center´Â Áú ½½¸µ ¼ö¼ú¿¡ ´ëÇÑ È¯ºÒÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀÌ ½ÃÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

Áú ½½¸µ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î °æÁú ½½¸µ ºÎ¹®Àº 2022³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ¼ö¼ú ½Ã°£ÀÌ Âª°í ÇÕº´Áõ ¹ß»ý·üÀÌ »ó´ëÀûÀ¸·Î ³·±â ¶§¹®ÀÔ´Ï´Ù.
  • À¯Çüº°·Î´Â Áß°£ ¿äµµ ½½¸µ ºÎ¹®ÀÌ 2022³â ¸ÅÃâ Á¡À¯À²¿¡¼­ Ãִ븦 Â÷ÁöÇß½À´Ï´Ù. ÀÌ ¼ºÀåÀº Àý°³Ã¢ÀÌ ÀÛ°í, Á¶ÀÛÀÌ ÀÛ°í, ÇØºÎ°¡ ÃÖ¼ÒÀÎ µîÀÇ ½Ã¼úÀÇ ÀÌÁ¡ ¶§¹®ÀÔ´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î º´¿ø ºÎ¹®Àº 2022³â ¸ÅÃâ¾× Á¡À¯À²¿¡¼­ Ãִ븦 Â÷ÁöÇß½À´Ï´Ù. ÀÌ ¼ºÀåÀº º´¿ø¿¡¼­ Á¦°øÇÏ´Â °í±Þ ½Ã¼³°ú ÀüÅëÀûÀÎ Áú ½½¸µ ½Ã¼úÀ»À§ÇÑ Àå±â ÀÔ¿øÀÇ Çʿ伺À¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù.
  • À¯·´Àº 2022³â¿¡ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ºÀåÀÇ ¿øµ¿·ÂÀº ÁÖ¿ä »ç¾÷ÀÚÀÇ Á¸Àç¿Í ȯÀÚ ¼öÀÇ ¸¹À½ µîÀÇ ¿äÀÎÀÔ´Ï´Ù. °Ô´Ù°¡ ´ç´¢º´°ú ½Å°æÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡°¡ ÀÌ Áö¿ª ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¸»·¹À̽þÆ, Áß±¹, Àεµ, Çѱ¹ µîÀÇ ±¹°¡¿¡¼­ ÀÇ·á ½Ã¼³ÀÌ ±Þ¼ÓÈ÷ Áøº¸Çϰí ÀÇ·á Á¦°ø¾÷ü ¹× »ç¾÷ ±â¾÷¿¡ ÀÇÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ 2023³âºÎÅÍ 2030³â¿¡ °ÉÃÄ À¯¸®ÇÑ ¼ºÀåÀÌ ¿¹»óµÈ´Ù µÇ¾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­ ¹× ¹üÀ§
  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • »ç¾÷ ȯ°æ ºÐ¼®
    • PESTLE ºÐ¼®
    • Porter's Five Forces ºÐ¼®
  • COVID-19 °¨¿°ÀÇ ¿µÇ⠺м®

Á¦4Àå Á¦Ç° ºñÁî´Ï½º ºÐ¼®

  • Áú ½½¸µ ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ÅÙ¼Ç ÇÁ¸® Áú Å×ÀÌÇÁ ½½¸µ
  • °æÆó¼â±Ù ½½¸µ
  • ¹Ì´Ï½½¸µ

Á¦5Àå À¯Çü ºñÁî´Ï½º ºÐ¼®

  • Áú ½½¸µ ½ÃÀå : À¯ÇüÀÇ º¯µ¿ ºÐ¼®
  • Áß´¢µµ ½½¸µ
  • Á¾·¡ÀÇ ½½¸µ

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • Áú ½½¸µ ½ÃÀå : ÃÖÁ¾ ¿ëµµÀÇ º¯µ¿ ºÐ¼®
  • º´¿ø
  • Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)

Á¦7Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

  • Áö¿ªº° Áú ½½¸µ ½ÃÀå Á¡À¯À²(2023³â ¹× 2030³â)
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ÀÇ ºÐ·ù
  • Àü·« ¸ÅÇÎ
    • ÇÕº´ ¹× Àμö
    • Äݶ󺸷¹À̼Ç
    • ½ÅÁ¦Ç° ¹ß¸Å
  • Âü°¡ ±â¾÷ÀÇ °³¿ä
    • Boston Scientific Corporation
    • Coloplast Corp
    • Promedon SA
    • AMI GmbH
    • Johnson &Johnson Services Inc.
    • Betatech Medical
    • Caldera Medical
    • Neomedic International
    • Cousin Surgery
    • Lotus Surgicals
    • UroCure
BJH 23.10.30

Vaginal Slings Market Growth & Trends:

The global vaginal slings market size is expected to reach USD 2.6 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.62% from 2023 to 2030. The key factors driving the market growth include changing woman's lifestyles and growing awareness of vaginal sling procedures or surgery. Moreover, rising demand for minimally invasive surgeries, growing female geriatric population, and increasing prevalence of stress urinary inconsistence are expected to boost the demand for the market over the forecast period.

The risk factors causing stress incontinence in women include uterine prolapse, diabetes, chronic coughing, pelvic surgery such as a hysterectomy, obesity, menopause, nerve injuries to lower back or pelvis, and pregnancy and childbirth (particularly vaginal birth). Furthermore, according to a John Wiley & Sons, Inc. research article, about 26% of women in emerging economies suffer from urinary incontinence, and the incidence of stress urinary incontinence (12.6%), is higher than that of mixed urinary incontinence (9.1%) and urgent urinary incontinence (5.3 %). Stress urinary incontinence can seriously affect a female's quality of life leading to mental disorders, a decrease in work productivity, an increase in mortality, and social isolation. Hence, the increasing incidence of urinary incontinence is significantly increasing the demand for vaginal slings, thereby driving the market.

Moreover, urinary incontinence is a very common disorder in the geriatric population. According to a National Statistical Office report in 2021, 71 million women were aged 60 and above in 2021, and the number is expected to reach 101 million by 2031. Thus, the growing female geriatric population is anticipated to offer lucrative opportunities for the market during the study period.

Additionally, vaginal sling surgery is found to be safe, efficient, and effective, and requires minimal procedure and recovery time of about 30 to 45 minutes. Owing to its minimally invasive procedure it has replaced conventional methods such as vaginal mesh and colposuspension. Therefore, rising demand for minimally invasive surgeries is fueling the market. Furthermore, the Centers for Medicare & Medicad Services (CMS) offer reimbursements for vaginal sling procedures. Such, factors are fueling the market.

Vaginal Slings Market Report Highlights:

  • Based on product, the transobturator slings segment dominated the market in 2022. The growth of the segment is attributed to the shorter operative time and a relatively lower complication rate
  • On the basis of type, the midurethral sling segment dominated the market with a maximum revenue share in 2022. The growth is attributed tothe advantages of the technique such as smaller incisions, minor manipulation, and minimal dissection
  • Based on end use, the hospitals segment dominated the market with a maximum revenue share in 2022. The growth is attributed tothe advanced facilities offered by hospitals and the requirement for longer stays in hospitals for traditional vaginal sling procedures
  • Europe dominated the market in 2022. The growth of the region is driven by factors such as the presence of key operating players and a large base of patient population. In addition, the increasing prevalence of chronic diseases such as diabetes and neurological diseases and the growing geriatric population are driving the market in the region
  • Asia Pacific is expected to witness lucrative growth from 2023 to 2030, owing to rapidly advancing healthcare facilities in countries such as Malaysia, China, India, and South Korea and growing investments by healthcare providers and operating players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Type Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
    • 1.8.1. Model Details
  • 1.9. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Restraint Analysis
  • 3.6. Business Environment Analysis
    • 3.6.1. PESTLE Analysis
    • 3.6.2. Porter's Five Forces Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Vaginal Slings Market: Product Movement Analysis
  • 4.2. Tension-Free Vaginal Tape Slings
    • 4.2.1. Tension-Free Vaginal Tape Slings Market, 2018 - 2030 (USD Million)
  • 4.3. Transobturator Slings
    • 4.3.1. Transobturator Slings Market, 2018 - 2030 (USD Million)
  • 4.4. Mini-Slings
    • 4.4.1. Mini-Slings Market, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Vaginal Slings Market: Type Movement Analysis
  • 5.2. Midurethral Sling
    • 5.2.1. Monthly Subscription Market, 2018 - 2030 (USD Million)
  • 5.3. Traditional Sling
    • 5.3.1. Traditional Sling Market, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. Vaginal Slings Market: End Use Movement Analysis
  • 6.2. Hospitals
    • 6.2.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 6.3. Clinics
    • 6.3.1. Clinics Market, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Ambulatory Surgical Centers Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Vaginal Slings Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Regulatory Framework/Scenario
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. U.S. Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Regulatory Framework/Scenario
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Canada Vaginal Slings Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Regulatory Framework/Scenario
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Germany Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Regulatory Framework/Scenario
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. UK Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Regulatory Framework/Scenario
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. France Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Regulatory Framework/Scenario
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Italy Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Regulatory Framework/Scenario
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Spain Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Regulatory Framework/Scenario
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Sweden Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Regulatory Framework/Scenario
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Norway Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.3.9. Denmark
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Regulatory Framework/Scenario
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Denmark Vaginal Slings Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework/Scenario
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Japan Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework/Scenario
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. China Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework/Scenario
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. India Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Regulatory Framework/Scenario
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Australia Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Regulatory Framework/Scenario
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Thailand Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Regulatory Framework/Scenario
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. South Korea Vaginal Slings Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework/Scenario
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Brazil Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework/Scenario
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Mexico Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework/Scenario
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Argentina Vaginal Slings Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework/Scenario
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. South Africa Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework/Scenario
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Saudi Arabia Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework/Scenario
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. UAE Vaginal Slings Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework/Scenario
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Kuwait Vaginal Slings Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. Merger& Acquisition
    • 8.2.2. Collaborations
    • 8.2.3. New Product Launch
  • 8.3. Participant's overview
    • 8.3.1. Boston Scientific Corporation
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Coloplast Corp
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Promedon S.A.
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. A.M.I. GmbH
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Johnson & Johnson Services Inc.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Betatech Medical
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Caldera Medical
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Neomedic International
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Cousin Surgery
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Lotus Surgicals
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. UroCure
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦